Skip to content

ATTR Amyloidosis in Elderly Patients With Aortic Stenosis

ATTR Amyloidosis in Elderly Patients With Aortic Stenosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04061213
Enrollment
489
Registered
2019-08-19
Start date
2019-08-26
Completion date
2022-12-31
Last updated
2022-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis Cardiac, Aortic Stenosis Symptomatic

Brief summary

Severe aortic stenosis is defined with a mean transvalvular pressure gradient (MTPG) \> 40mmHg and a calculated aortic valve area of \< 1cm2. However, a considerable proportion of patients do have a MTPG \< 40mmHg due to a reduced stroke volume (stroke volume indexed to body surface area ≤ 35ml/m2) despite a normal left ventricular ejection fraction (LVEF \> 50%). This entity is termed paradoxical low flow low gradient aortic stenosis (PLFLG AS) and is associated with a worse prognosis. ATTR amyloidosis is a disease of the elderly and might coexist in patients with severe aortic stenosis. Case reports and small observational studies suggest that senile ATTR amyloidosis could be frequent but underdiagnosed in patients with aortic stenosis. There is significant overlap between PLFLG AS and cardiac amyloidosis with regard to symptoms, increasing prevalence with age, concentric hypertrophy, impaired diastolic filling of the left ventricle (LV), as well as longitudinal LV dysfunction despite preserved ejection fraction - all features, which lead to a reduction in stroke volume, the underlying mechanism of the low flow condition as observed in PLFLG AS patients.

Interventions

DIAGNOSTIC_TESTTc-99m-DPD scintigraphy

Myocardial scintigraphy

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Symptomatic, severe aortic stenosis

Exclusion criteria

* More than mild valvular disease of any other valve * Other severe disease with a life expectancy \< 1 year * Participating in trial interfering with routine clinical practice or use of a non-CE marked device

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with grade 2 or 3 cardiac uptake in scintigraphy and without pathological light chains in immunological assaysIn-Hospital [7 days]Evaluation of incidence rate

Secondary

MeasureTime frameDescription
All-cause and cardiovascular mortality30 days, 12monthsClinical Endpoints
CPET - maximal exercise capacityIn-Hospital [7 days]Functional Endpoints

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026